Wanner C - Search Results

1

Genome-wide association study identifies 3 genomic loci significantly associated with serum levels of homoarginine: the AtheroRemo Consortium.

Kleber ME, Seppälä I, Pilz S, Hoffmann MM, Tomaschitz A, Oksala N, Raitoharju E, Lyytikäinen LP, Mäkelä KM, Laaksonen R, Kähönen M, Raitakari OT, Huang J, Kienreich K, Fahrleitner-Pammer A, Drechsler C, Krane V, Boehm BO, Koenig W, Wanner C, Lehtimäki T, März W, Meinitzer A. Kleber ME, et al. Among authors: wanner c. Circ Cardiovasc Genet. 2013 Oct;6(5):505-13. doi: 10.1161/CIRCGENETICS.113.000108. Epub 2013 Sep 18. Circ Cardiovasc Genet. 2013. PMID: 24047826

2

The metabolic burden of diabetes and dyslipidaemia in chronic kidney disease.

Krane V, Wanner C. Krane V, et al. Among authors: wanner c. Nephrol Dial Transplant. 2002;17 Suppl 11:23-7. doi: 10.1093/ndt/17.suppl_11.23. Nephrol Dial Transplant. 2002. PMID: 12386253 Review.

3

Non-high-density lipoprotein cholesterol: a target of lipid-lowering in dialysis patients.

Wanner C, Krane V. Wanner C, et al. Am J Kidney Dis. 2003 Mar;41(3 Suppl 1):S72-5. doi: 10.1053/ajkd.2003.50089. Am J Kidney Dis. 2003. PMID: 12612957 Review.

4

Statins and aspirin in chronic kidney disease: what does the UK-HARP-I trial tell us?

Krane V, Wanner C. Krane V, et al. Among authors: wanner c. Am J Kidney Dis. 2005 Mar;45(3):607-9. doi: 10.1053/j.ajkd.2005.01.011. Am J Kidney Dis. 2005. PMID: 15754285 No abstract available.

5

Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis.

Wanner C, Krane V, März W, Olschewski M, Mann JF, Ruf G, Ritz E; German Diabetes and Dialysis Study Investigators. Wanner C, et al. N Engl J Med. 2005 Jul 21;353(3):238-48. doi: 10.1056/NEJMoa043545. N Engl J Med. 2005. PMID: 16034009 Free article. Clinical Trial.

6

Hidden population substructures in an apparently homogeneous population bias association studies.

Berger M, Stassen HH, Köhler K, Krane V, Mönks D, Wanner C, Hoffmann K, Hoffmann MM, Zimmer M, Bickeböller H, Lindner TH. Berger M, et al. Among authors: wanner c. Eur J Hum Genet. 2006 Feb;14(2):236-44. doi: 10.1038/sj.ejhg.5201546. Eur J Hum Genet. 2006. PMID: 16333311

7

Lessons learnt from the 4D trial.

Wanner C, Krane V. Wanner C, et al. Nephrol Ther. 2006 Feb;2(1):3-7. doi: 10.1016/j.nephro.2006.01.002. Epub 2006 Feb 24. Nephrol Ther. 2006. PMID: 16895709 Clinical Trial. English, French.

8

At which stage of chronic kidney disease should dyslipidemia be treated?

Krane V, Wanner C. Krane V, et al. Among authors: wanner c. Nat Clin Pract Nephrol. 2006 Apr;2(4):176-7. doi: 10.1038/ncpneph0129. Nat Clin Pract Nephrol. 2006. PMID: 16932418 No abstract available.

9

Dyslipidemia, inflammation and dialysis outcomes: what we know now.

Krane V, Drechsler C, Wanner C. Krane V, et al. Among authors: wanner c. Curr Opin Nephrol Hypertens. 2006 Nov;15(6):566-70. doi: 10.1097/01.mnh.0000247501.41420.dd. Curr Opin Nephrol Hypertens. 2006. PMID: 17053468 Review.

10

Lipid metabolism in chronic kidney disease: the role of statins in cardiovascular risk.

Wanner C, Drechsler C, Krane V. Wanner C, et al. J Ren Nutr. 2007 Jan;17(1):75-8. doi: 10.1053/j.jrn.2006.10.012. J Ren Nutr. 2007. PMID: 17198938 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,013 results

Search Page